In a nutshell This study investigated if dulaglutide is a safe and effective medication for the treatments of type 2 diabetes. They found that dulaglutide effectively improved blood glucose control regardless of gender or disease duration. Some background Management of blood glucose (sugar) levels is important in type 2 diabetes. To do this,...
Read MoreIn a nutshell This study compared data from clinical trials investigating if dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with a greater risk of arthralgia (joint pain) in type 2 diabetes patients. They found there was slight increased risk for developing arthralgia in patients taking DPP-4 inhibitors. Some background Managing...
Read MoreIn a nutshell This study investigated if dapagliflozin reduces the risk of developing cardiovascular complications in patients with type 2 diabetes. They found that dapagliflozin was associated with a lower risk of non-fatal heart attack and stroke compared to dipeptidyl peptidase-4 inhibitors (DPP-4i). Some background Cardiovascular (CV, heart...
Read More
In a nutshell This study investigated the safety and effectiveness of semaglutide on glycemic control in insulin-naïve patients with type 2 diabetes. They found that semaglutide improved glycemic (blood sugar) control and was well-tolerated by patients. Some background Controlling blood glucose levels is essential in type 2 diabetes. The...
Read More
In a nutshell This study investigated if administering fast-acting insulin aspart (faster aspart) at mealtimes improved glycemic control in patients with type 2 diabetes. They found that faster aspart improved glycemic control compared to basal (long-lasting) insulin alone, but with increased hypoglycemia and weight gain. Some background...
Read MoreIn a nutshell This study investigated if a low carbohydrate diet improved glycemic control (blood sugar) and cardiovascular (heart and circulatory system) parameters in type 1 diabetes patients. They found that a low carbohydrate diet resulted in improved glycemic control with no effect on cardiovascular markers. Some background Glycemic...
Read MoreIn a nutshell This study investigated whether SGLT2 (sodium-glucose co-transporter-2) inhibitors reduced the risk of cardiovascular complications in patients with type 2 diabetes. They found that SGLT2 inhibitors were associated with reduced risk of cardiovascular disease and mortality compared to other treatment types. Some background...
Read More
In a nutshell This study investigated the safety of Januvia (sitagliptin) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). They determined that sitagliptin was safe in these patients. Some background CKD is a major complication of T2D. It can lower the quality of life and increase the mortality risk. CKD can also influence...
Read More
In a nutshell This study investigated the effectiveness and safety of the artificial pancreas (APs) in people with type 1 diabetes (T1D). It was determined that APs improve control of glucose levels, without increasing the insulin dose. Some background A traditional insulin pump is a small device that continuously delivers insulin, without...
Read More
In a nutshell This study compared the effectiveness and safety of fast-acting insulin aspart (faster aspart) to conventional insulin aspart (IAsp) in people with type 1 diabetes (T1D). It determined that faster aspart could control blood glucose levels as well as IAsp, without increasing the risk of side effects. Some background Reducing HbA1c...
Read MoreIn a nutshell This study examined if eating a divided dinner late at night had an impact on blood sugar levels in patients with type 2 diabetes. They found that patients who ate a divided meal late at night improved increased blood sugar (hyperglycemia) following the meal (postprandial). Some background Postprandial hyperglycemia refers to...
Read More
In a nutshell This study investigated if insulin degludec was as effective as insulin glargine U100 in reducing rates of hypoglycemia (low blood sugar) in patients with type 1 diabetes. They found that patients receiving insulin degludec had a reduced risk of hypoglycemia compared to those receiving insulin glargine U100. Some background...
Read More
